Mouse anti-Mouse/Rat CD90.1 Monoclonal Antibody for FC - P01831

Core Product Specifications and Parameters

Biological Background: Thy-1 Membrane Glycoprotein Function and Localization

• Thy-1 (CD90) is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein belonging to the immunoglobulin superfamily.
• It is expressed on the cell surface and anchored to the membrane via a GPI linkage.
• Thy-1 plays a role in cell-cell and cell-ligand interactions, particularly during synaptogenesis and other events in the brain.
• The protein contains an immunoglobulin-like domain, suggesting functions in cell adhesion and signal transduction.
• Thy-1 is subject to post-translational modifications, including disulfide bond formation and pyrrolidone carboxylic acid modification.
• The mouse Thy-1 protein has a molecular weight of approximately 18 kDa.
• It has been characterized through direct protein sequencing.

Experimental Guidance and Technical Tips

• The antibody was generated against recombinant mouse/rat CD90.1 and is specific for the CD90.1 alloantigen (distinct from CD90.2).
• For flow cytometry, perform antibody titration to determine the optimal concentration for your specific cell type and experimental conditions.
• Since Thy-1 is a GPI-anchored surface protein, permeabilization is typically not required for membrane staining.
• Consider including isotype controls and fluorescence-minus-one (FMO) controls to ensure accurate gating.
• Validate the antibody in the relevant mouse or rat sample system to confirm expected staining patterns in neuronal and immune cell populations.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio is your one-stop sourcing partner for IVD raw materials, offering validated antibodies and bulk ancillary reagents to support every stage of diagnostic development. The Mouse anti-Mouse/Rat CD90.1 mAb provides a reliable tool for flow cytometry analysis of Thy-1 in neurobiology and immunology research. From monoclonal antibodies to rare target raw materials, CamelBio streamlines procurement so you can accelerate innovation from concept to clinic.